Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISH 2022 | Novel targets in CAR-T therapy for multiple myeloma: integrin beta-7 & CD98 heavy chain

Naoki Hosen • 8 Oct 2022
ISH 2022
Multiple Myeloma CAR-T

Naoki Hosen, PhD, Osaka University Graduate School of Medicine, Osaka, Japan, explains the rationale for targeting novel antigens for CAR-T therapy in multiple myeloma, including activated integrin beta-7 and a glycoform of the CD98 heavy chain. This interview took place at the 38th World Congress of the International Society of Hematology 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Naoki Hosen

0:43
Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALL
Naoki Hosen • 8 Oct 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals